Source link : https://www.newshealth.biz/health-news/metastasis-directed-therapy-ups-pfs-in-pancreatic-cancer/
TOPLINE: Adding metastasis-directed therapy (MDT) to systemic therapy improves progression-free survival (PFS) to 10.3 months vs 2.5 months with systemic therapy alone. The study involved 41 patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC). METHODOLOGY: Researchers conducted a phase 2 multicenter, randomized basket trial involving 41 patients with oligometastatic PDAC in the EXTEND trial. Participants were […]
Author : News Health
Publish date : 2024-08-07 10:12:50
Copyright for syndicated content belongs to the linked Source.